| Breast cancer is the second deadliest cancer in the United States and is classified into four main subtypes including HER2-positive breast cancer. There have been a number of HER2-targeted therapeutic treatments that were discovered, but they are expensive and patients frequently exhibit a resistance for these treatments. To alleviate patients undergoing expensive therapy with the possibility of not benefitting from the treatment, it is important to understand the cooperation between HER2 and mutp53, a tumor suppressor gene that is mutated in the majority of breast cancers. Analysis of scientific articles illustrate that HER2 and mutp53 cooperate to promote tumorigenesis via the master transcriptional regulator of the heat shock response, HSF1 in HER2-positive breast cancer. Therefore, this HSFS1-mediated oncogenic cooperation between mutp53 and HER2 may amplify HER2 signaling and sensitize breast cancer cells to HER2 targeted therapies. Thus, mutp53 can be used as a potential biomarker for successful treatment of HER2-positive breast cancer. |
